Treatment of experimental non-alcoholic steatohepatitis by targeting α7 nicotinic acetylcholine receptor-mediated inflammatory responses in mice.
Mol Med Rep
; 12(5): 6925-31, 2015 Nov.
Article
en En
| MEDLINE
| ID: mdl-26397391
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is one of the most common types of liver disease, affecting up to 30% of the general population worldwide. Nonalcoholic steatohepatitis (NASH) is a severe form of NAFLD without any effective therapies available. The present study showed that activation of α7nicotinic acetylcholine receptor (α7 nAChR) may be a novel potential strategy for NASH therapy. Treatment with the α7 nAChR agonist nicotine for three weeks obviously attenuated hepatic steatosis in a high-fat dietinduced mouse model of NASH. Investigation of the underlying mechanism showed that nicotine reduced the secretion of the proinflammatory cytokines tumor necrosis factor α and interleukin 6 in vitro and in vivo. Inflammation is an integral part of NASH and is the most prevalent form of hepatic pathology found in the general population; therefore, the effect of α7 nAChR activation against NASH may be ascribed to its antiinflammatory effects. In addition, the present study showed that nicotinestimulated α7 nAChR activation led to a significant downregulation of nuclear factor kappa B (NKκB) and extracellular signal-regulated kinase (ERK). It therefore appeared that activation of α7 nAChR suppressed the production of proinflammatory cytokines through NKκB and ERK pathways. In conclusion, the present study indicated that targeting α7 nAChR may represent a novel treatment strategy for NASH.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Agonistas Nicotínicos
/
Receptor Nicotínico de Acetilcolina alfa 7
/
Enfermedad del Hígado Graso no Alcohólico
/
Hígado
/
Antiinflamatorios
/
Nicotina
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
Mol Med Rep
Año:
2015
Tipo del documento:
Article